ClinConnect ClinConnect Logo
Search / Trial NCT06036017

Care Bundle's Impact on Delirium Prevention in CABG Patients

Launched by İSLAM ELAGÖZ · Sep 11, 2023

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Coronary Artery Bypass Graft Surgery Care Bundle Application Delirium Prevention Postoperative Care Cardiac Surgery Intensive Care Quality Of Care Music

ClinConnect Summary

This clinical trial is looking at how a special care package can help prevent delirium in patients who are having coronary artery bypass graft (CABG) surgery. Delirium is a state of confusion that can happen after surgery, especially in older patients or those with serious health issues. The care package includes things like managing pain effectively, helping patients get good sleep, encouraging them to move around, keeping them oriented (aware of their surroundings), and making sure they receive the right medications.

To be eligible for this study, participants must be adults over the age of 18 who are having their first open-heart surgery and are considered low-risk for complications. They need to have a family member available to help them after the surgery, and they must agree to take part in the research. If you join this study, you can expect to receive the care package designed to improve your recovery and reduce the chances of experiencing confusion after your surgery. This research is important because it could lead to better outcomes for patients and help hospitals use their resources more effectively.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participants and Sample Criteria Inclusion criteria for the study:
  • Over 18 years of age,
  • Considered as a low-risk group according to American Society of Anesthesiologists (ASA)
  • I-II and EUROSCORE scores
  • Undergoing open-heart surgery for the first time
  • Having an operation with on-pump and median sternotomy technique,
  • Mild and moderate hypothermia applied,
  • One to three coronary artery bypass grafts performed,
  • Left internal mammary artery and saphenous vein graft applied,
  • Surgery initiated between 08:00-12:00 hours,
  • Having no psychiatric diagnosis and therefore no drug therapy,
  • Not using corticosteroid derivative drugs,
  • No complications observed that may affect the surgery and ICU process,
  • Having a family member who can support the patient in the postoperative wake-up process,
  • Patients who voluntarily agree to participate in the research will be included.
  • Exclusion Criteria:
  • Extended surgery due to complications,
  • Completion of the intraoperative process falls into the evening hours (after 16:00),
  • Consciousness level after extubation prevents participation in the study (Glasgow Coma Score \<15),
  • Corticosteroid derivative drugs applied at any stage of the perioperative process, Surgery is canceled,
  • No family member is available to stay in the intensive care unit,
  • Wishing to withdraw from the research at any stage after voluntarily agreeing to participate in the study,
  • At any stage of the research, patients who do not wish to use earplugs or listen to music and wish to withdraw from the research, their data will be excluded from the study.

About İslam Elagöz

Islam Elagöz is a dedicated clinical trial sponsor specializing in the advancement of innovative therapies through rigorous research and development. With a focus on enhancing patient outcomes, the organization is committed to conducting high-quality clinical trials that adhere to ethical standards and regulatory requirements. By fostering collaborations with healthcare professionals and leveraging cutting-edge methodologies, Islam Elagöz aims to contribute to the scientific community and improve health solutions across various medical fields.

Locations

Kilis, , Turkey

Patients applied

0 patients applied

Trial Officials

İslam Elagoz, Ress. ass.

Study Chair

kilis 7 Aralik Univ.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported